Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) was down 2.7% during mid-day trading on Tuesday . The stock traded as low as $15.22 and last traded at $15.22. Approximately 4,367 shares traded hands during mid-day trading, a decline of 97% from the average daily volume of 137,039 shares. The stock had previously closed at $15.64.
Enliven Therapeutics Price Performance
The firm has a market cap of $609.02 million, a price-to-earnings ratio of 5.23 and a beta of 1.08. The firm’s 50 day moving average price is $17.25 and its two-hundred day moving average price is $19.39.
Enliven Therapeutics (NASDAQ:ELVN – Get Free Report) last announced its earnings results on Thursday, August 10th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.40) by ($0.01). On average, analysts anticipate that Enliven Therapeutics, Inc. will post -2.12 earnings per share for the current year.
Insider Buying and Selling
Institutional Inflows and Outflows
Hedge funds have recently added to or reduced their stakes in the stock. Fairmount Funds Management LLC purchased a new position in shares of Enliven Therapeutics during the 1st quarter worth approximately $42,156,000. Logos Global Management LP purchased a new position in shares of Enliven Therapeutics during the 1st quarter worth approximately $8,787,000. Boxer Capital LLC purchased a new position in shares of Enliven Therapeutics during the 1st quarter worth approximately $15,563,000. Commodore Capital LP purchased a new position in shares of Enliven Therapeutics during the 1st quarter worth approximately $37,917,000. Finally, Metropolitan Life Insurance Co NY purchased a new position in shares of Enliven Therapeutics during the 2nd quarter worth approximately $26,000. 95.08% of the stock is owned by hedge funds and other institutional investors.
About Enliven Therapeutics
Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene.
- Five stocks we like better than Enliven Therapeutics
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Hold-It-Forever AutoZone Pulls into Buy Zone
- How to Build Wealth with the Dividend Aristocrat Index
- Virtual Riches: 3 Stocks Leading the VR Revolution
- What Are Dividend Challengers?
- 5 eCommerce Companies that need to be on Your Watch List
Receive News & Ratings for Enliven Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enliven Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.